NCT05700916 Evaluation of Milk Polar Lipids in Dyslipidemic Adults With Abdominal Obesity
| NCT ID | NCT05700916 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | University of Connecticut |
| Condition | Dyslipidemias |
| Study Type | INTERVENTIONAL |
| Enrollment | 130 participants |
| Start Date | 2023-10-20 |
| Primary Completion | 2026-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 130 participants in total. It began in 2023-10-20 with a primary completion date of 2026-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The major objective of this project is to examine whether daily consumption of milk polar lipids (MPLs) influences cardiometabolic risk factors.
Eligibility Criteria
Inclusion Criteria: * LDL-C ≥ 130 mg/dL * Waist circumference ≥ 88 cm for women, ≥ 102 cm for men * Aged 18 to 70 years Exclusion Criteria: * Renal disease * Liver disease * Diabetes * Heart disease * Stroke * Cancer * Eating disorders * Thyroid disease * Gut-associated pathologies * Autoimmune diseases * Chronic inflammatory diseases * Scleroderma * Gallbladder disease * Blood clotting disorders * Intravenous drug use * Fasting plasma/serum triglycerides \>500 mg/dL * Fasting plasma/serum glucose \>126 mg/d * Weight changes \>10% over last 4 weeks * Oral antibiotics use up to 1 month prior to and during study * Allergy or intolerance to milk products * Taking lipid-lowering medications (e.g., statins, fibrates) * Taking anti-inflammatory medications (e.g., corticosteroids) * Taking medications which primarily affect blood clotting (e.g., warfarin).
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05700916 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Dyslipidemias. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05700916 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT05700916 currently recruiting?
Yes, NCT05700916 is actively recruiting participants. Contact the research team at christopher.blesso@uconn.edu for enrollment information.
Where is the NCT05700916 trial being conducted?
This trial is being conducted at Storrs, United States.
Who is sponsoring the NCT05700916 clinical trial?
NCT05700916 is sponsored by University of Connecticut. The trial plans to enroll 130 participants.